

Results for announcement to the market				
AFT Pharmaceuticals Limite				
Reporting Period		12 months to 31 March 2024		
Previous Reporting Period		12 months to 31 March 2023		
Currency		NZ\$		
Currency		Amount Percentage change		
		(000s)	unt	i ercentage change
Revenue from continuing operations		\$195,411		Up 25%
Total Revenue		\$195,411	Up 25%	
Net profit/(loss) from continuing operations		\$15,609	Up 46%	
Total net profit/(loss)		\$15,609	Up 46%	
Interim/Final Dividend				
Quoted Equity Securities:				
Amount per Quoted Equity Security		\$0.01100000		
Imputed amount per Quoted Equity Security		No imputation		
Record Date		19/06/2023		
Dividend Payment Date		04/07/2023		
,		0 11 0 1 7 2 0 2 0		
		Current period	Prio	r comparable period
Net tangible assets per Quo Security	ted Equity		Prio	r comparable period \$0.26
Net tangible assets per Quo	Accompanying to consolidated find March 2024. The commentary data information requand Appendix 2. Pursuant to ASX	\$0.33 his announcement ancial statements for the see financial statements are 23 May 2024 provincements in accordance (Clisting rule 1.15.3 continues to comply	are the or the tv nents ar ovide th ance wi	\$0.26 Group's audited velve months ended 31 and the full year results be balance of th NZX Listing Rules armaceuticals Limited
Net tangible assets per Quo Security A brief explanation of any of the figures above necessary to enable the	Accompanying to consolidated find March 2024. The commentary data information requand Appendix 2. Pursuant to ASX confirms that it dexchange (NZX	\$0.33 his announcement ancial statements for the see financial statements are 23 May 2024 provincements in accordance (Clisting rule 1.15.3 continues to comply	are the or the tv nents ar ovide th ance wi	\$0.26 Group's audited velve months ended 31 and the full year results be balance of th NZX Listing Rules armaceuticals Limited
Net tangible assets per Quo Security A brief explanation of any of the figures above necessary to enable the figures to be understood	Accompanying to consolidated find March 2024. The commentary data information requand Appendix 2. Pursuant to ASX confirms that it dexchange (NZX tement	\$0.33 his announcement ancial statements for the see financial statements are 23 May 2024 provincements in accordance (Clisting rule 1.15.3 continues to comply	are the or the tv nents ar ovide th ance wi	\$0.26 Group's audited velve months ended 31 and the full year results be balance of th NZX Listing Rules armaceuticals Limited
Net tangible assets per Quo Security A brief explanation of any of the figures above necessary to enable the figures to be understood Authority for this announce Name of person authorised	Accompanying to consolidated find March 2024. The commentary data information requand Appendix 2. Pursuant to ASX confirms that it does not confirm that it does not confir	current period \$0.33 his announcement ancial statements for ese financial statement and 23 May 2024 provincements in accordance (I listing rule 1.15.3 continues to comply Main Board).	are the tweets are ovide the ance with the with the Chief Fire	\$0.26 Group's audited velve months ended 31 and the full year results he balance of th NZX Listing Rules harmaceuticals Limited e rules of its home
Net tangible assets per Quo Security A brief explanation of any of the figures above necessary to enable the figures to be understood Authority for this announce Name of person authorised announcement	Accompanying to consolidated find March 2024. The commentary data information requand Appendix 2. Pursuant to ASX confirms that it does not confirm that it does not confir	current period \$0.33 his announcement ancial statements for ese financial statement and 23 May 2024 provincements in accordance (Iisting rule 1.15.3 continues to comply Main Board). Malcolm Tubby Malcolm Tubby, Continues, Continues, Continues, Continues to Comply Main Board).	are the tweets are ovide the ance with the with the Chief Fire	\$0.26 Group's audited velve months ended 31 and the full year results he balance of th NZX Listing Rules harmaceuticals Limited e rules of its home
Net tangible assets per Quo Security A brief explanation of any of the figures above necessary to enable the figures to be understood Authority for this announce Name of person authorised announcement Contact person for this announce the figures and the figures above necessary to enable the figures to be understood	Accompanying to consolidated find March 2024. The commentary data information requand Appendix 2. Pursuant to ASX confirms that it does not confirm that it does not confir	current period \$0.33 his announcement ancial statements for the see financial statement and 23 May 2024 provincements in accordance (a listing rule 1.15.3 continues to comply Main Board). Malcolm Tubby Malcolm Tubby AFT Pharmaceuti	are the to the to hents are the trovide the ance with the control of the control	\$0.26 Group's audited velve months ended 31 and the full year results he balance of th NZX Listing Rules harmaceuticals Limited e rules of its home

Audited financial statements accompany this announcement.